Immunoprecise Antibodies Stock Target Price and Analyst Consensus


USD 3.96  0.03  0.75%   

The current analyst and expert consensus on Immunoprecise Antibodies is Strong Buy, with 0 strong sell and 1 strong buy opinions. The current projected Immunoprecise Antibodies target price consensus is 12.0 with 1 analyst opinions. The most common way Immunoprecise Antibodies analysts use to provide recommendation to the public is financial statements analysis. Many experts also interview Immunoprecise Antibodies executives and customers to further validate their buy or sell advice. Please note, the number of analysts providing the opinion is not sufficient to provide adequate consensus on Immunoprecise Antibodies. We encourage you to use your own analysis of Immunoprecise Antibodies to validate this buy or sell advice. Immunoprecise Antibodies buy-or-sell recommendation module provides average expert sentiment on the projected Immunoprecise Antibodies target price to derive its highest and lowest estimates based on projected price volatility of 0.0. Please see Macroaxis Advice on Immunoprecise Antibodies to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon.
As of June 29, 2022, Gross Profit is expected to decline to about 11.8 M. In addition to that, Profit Margin is expected to decline to -0.51. Immunoprecise Antibodies Current Assets are projected to increase significantly based on the last few years of reporting. The past year's Current Assets were at 56.19 Million. The current year Assets Non Current is expected to grow to about 16.7 M, whereas Accumulated Other Comprehensive Income is forecasted to decline to (667.1 K).

Immunoprecise Antibodies Target Price Consensus

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Immunoprecise target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Immunoprecise target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Number of OpinionsOne
Lowered Outlook0
Raized Outlook0
Strong Buy
Most Immunoprecise analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Immunoprecise stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Immunoprecise Antibodies, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice   Exposure   Valuation

Immunoprecise Antibodies Target Price Projection

Immunoprecise Antibodies' current and average target prices are 3.96 and 12.00, respectively. The current price of Immunoprecise Antibodies is the price at which Immunoprecise Antibodies is currently trading. On the other hand, Immunoprecise Antibodies' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.

Current Price

Immunoprecise Antibodies Market Quote on 29th of June 2022

Low Price3.94Odds
High Price4.04Odds


Target Price

Analyst Consensus On Immunoprecise Antibodies Target Price

Low Estimate12.0Odds
High Estimate12.0Odds
Number of AnalystsOne
Standard Deviation0.0


Note that most analysts generally publish their price targets in research reports on specific companies, along with recommendations for the company's stock.Although price targets are often quoted in the financial news media, there could be a delay between the publication of the latest analyst outlook on Immunoprecise Antibodies and the information provided on this page.

Immunoprecise Antibodies Analyst Ratings

Immunoprecise Antibodies' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Immunoprecise Antibodies stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Immunoprecise Antibodies' financials, market performance, and future outlook by experienced professionals. Immunoprecise Antibodies' historical ratings below, therefore, can serve as a valuable tool for investors.

Analyst Consensus Breakdown

Average Consensus Estimates

About Immunoprecise Antibodies Target Price Projections

Immunoprecise Antibodies's target price is an analyst's projection of its future price. Price targets can be assigned to all types of securities, from complex investment products to stocks such as Immunoprecise Antibodies and even bonds. If the target price is unavailable, it is most likely because there were not enough analyst opinions to come up with a consensus estimate. When setting a price target estimate, an analyst is trying to determine what the Stock is worth and where the price will be in a year from now. Generally, the target price of Immunoprecise depends on its intrinsic valuation, beta (i.e., risk over market), and overall volatility. Most analysts publish their price targets in research reports on specific companies, along with their buy, hold, or sell recommendations. Stock price targets are often quoted in the financial news media. Macroaxis uses multiple feeds to provide overall target price projection for Immunoprecise Antibodies including its fundamental analysis.
 2020 2021 2022 (projected)
Book Value per Share3.463.973.25
Asset Turnover0.380.340.36

Additional Immunoprecise Antibodies Value Projection Modules

Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Immunoprecise Antibodies is a key component of Immunoprecise Antibodies valuation and have some predictive power on the future returns of a Immunoprecise Antibodies.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Immunoprecise Antibodies' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Immunoprecise Antibodies in the context of predictive analytics.
LowEstimated ValueHigh
LowReal ValueHigh
LowNext ValueHigh
Band Projection (param)
LowerMiddle BandUpper
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Immunoprecise Antibodies. Your research has to be compared to or analyzed against Immunoprecise Antibodies' peers to derive any actionable benefits. When done correctly, Immunoprecise Antibodies' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Immunoprecise Antibodies.

Trending Themes

If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment.
Macroaxis Index
Invested over 20 shares
Please see Macroaxis Advice on Immunoprecise Antibodies to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. Note that the Immunoprecise Antibodies information on this page should be used as a complementary analysis to other Immunoprecise Antibodies' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Complementary Tools for Immunoprecise Stock analysis

When running Immunoprecise Antibodies price analysis, check to measure Immunoprecise Antibodies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunoprecise Antibodies is operating at the current time. Most of Immunoprecise Antibodies' value examination focuses on studying past and present price action to predict the probability of Immunoprecise Antibodies' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunoprecise Antibodies' price. Additionally, you may evaluate how the addition of Immunoprecise Antibodies to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Equity Valuation
Check real value of public entities based on technical and fundamental data
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Bond Directory
Find actively traded corporate debentures issued by US companies
The data published in Immunoprecise Antibodies' official financial statements usually reflect Immunoprecise Antibodies' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Immunoprecise Antibodies. For example, before you start analyzing numbers published by Immunoprecise accountants, it's critical to develop an understanding of what Immunoprecise Antibodies' liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Immunoprecise Antibodies' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Immunoprecise Antibodies' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Immunoprecise Antibodies' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Immunoprecise Antibodies. Please utilize our Beneish M Score to check the likelihood of Immunoprecise Antibodies' management to manipulate its earnings.